Clinical Trial Update: A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy [Phase 1]

View source ↗

Summary

Phase 1 trial to assess the safety and tolerability of RAG-01 in patients with non-muscle-invasive bladder cancer unresponsive to BCG therapy; recruitment is on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• RAG-01

Snippet

Sponsor: Ractigen Therapeutics. | Conditions: Non-Muscle-Invasive Bladder Cancer (NMIBC) | Phase 1 | Status: RECRUITING